SILVER SPRING
BLA accepted for Nanoscope's Mogenry
- Sponsor
- Nanoscope Therapeutics
- Drug
- Mogenry
- Indication
- retinitis pigmentosa
FDA accepts Nanoscope Therapeutics' biologics license application for Mogenry in retinitis pigmentosa.
What this means
Mogenry is a gene therapy designed to restore vision in patients with retinitis pigmentosa, a genetic eye disease that causes blindness. The FDA has accepted Nanoscope's application for review, starting the formal evaluation process. If approved, it could offer a new treatment option for a condition that currently has no cure.